The FDA has approved trastuzumab deruxtecan (T-DXd) for patients with HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer based on DESTINY-Breast06 trial results. #BreastCancer #Oncology
#BreastCancer #Oncology